This inventor holds 4 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Eli Lilly and Company. Active years: 2015-2026.
Company Filing History:
Years Active: 2015-2026
Title: The Innovative Contributions of Daniel Scott Girard
Introduction
Daniel Scott Girard, an accomplished inventor based in San Diego, California, has made significant strides in the field of biotechnology. With a focus on developing innovative treatments for various medical conditions, Girard holds three patents that demonstrate his commitment to advancing medical science and improving patient care.
Latest Patents
Daniel Scott Girard's most recent patents showcase his expertise in antibody development. His first notable patent is for an Anti-TrkA antibody, designed to Target tropomyosin receptor kinase (TrkA). This invention includes compositions comprising these antibodies and methods for utilizing them in the treatment of diverse types of pain, including post-surgical pain, rheumatoid arthritis pain, neuropathic pain, and osteoarthritis pain.
Another groundbreaking patent awarded to Girard focuses on nucleic acids encoding antibodies that bind to IL-23. This invention provides an antibody that selectively targets the p19 subunit of human IL-23, exhibiting high affinity and neutralizing properties. The potential applications of this antibody extend to the treatment or prevention of autoimmune and inflammatory conditions such as multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, and more. Additionally, this invention holds promise in cancer treatment.
Career Highlights
Daniel Scott Girard is currently associated with Eli Lilly and Company, a leading player in the biotechnology industry. Through his work, he is dedicated to addressing medical challenges and contributing to the development of innovative therapies that can significantly enhance patients' quality of life.
Collaborations
Throughout his career, Girard has collaborated with talented coworkers, including Catherine Brautigam Beidler and Stuart W. Bright. These partnerships have enhanced his research efforts and fostered a collaborative environment conducive to innovation.
Conclusion
In conclusion, Daniel Scott Girard exemplifies the spirit of innovation in the biomedical field. His contributions through his patents reflect a commitment to tackling complex medical issues and embody the essence of creativity in science. With his ongoing work at Eli Lilly and Company, Girard continues to pave the way for future advancements in medical treatments and therapies.